Master Good Contact Points to Engage with Your Patients Directly

Risk minimisation measures, training, and communication with patients

What are the applications of AI using social media for signal detection?

Currently, it is under discussion the monitoring of social media from a pharmacovigilance perspective. Using AI to monitor signal detection related to social media should be analysed in detail from pharmacovigilance department.

How should the pharma industry move in the direction of designing a patient-centred pharmacovigilance system?

Pharma company should engage the patient directly, the patient association are a good contact point for MAH in order to be closer to the patient. Additional risk minimisation measures, training and communication with a patient could improve the centricity of patients in the pharmacovigilance system.

What is the future global role of pharmacovigilance in boosting market access?

Global pharmacovigilance will be involved in the evaluation of the business for a new market, considering the current legislation for each country and their local requirements.

Andrea is also joining our 10th Annual Risk Management and Pharmacovigilance Summit on 10th – 11th May 2023 in Vienna, as one of the keynote speakers to share a case study on Pharmacovigilance and Social Media, covering the topics of PV responsibilities on social media, social media classification from a PV perspective and workflow examples of social media screening.

Visit event website

Andrea Oliva is a Head of Pharmacovigilance, Italy, at Mylan Italia, a Viatris company. He graduated from Milan University with a degree in Pharmaceutical Biotechnology, a bachelor’s degree in Biology Applied to Biomedical Research and a PhD in pharmacovigilance and pharmacoepidemiology, started his work experience as a researcher in the field of infectious diseases. From 2009 he starts in the technical/scientific management team as QPPV deputy and is responsible for Medical Information at Teofarma. After a brief period in regulatory affairs at DOC Generici, he joints GB Pharma (consultant company and CRO), assuming the role of QPPV and Italian PV responsible for different companies. In the last period at GB Pharma, he is also the coordinator of the Regulatory Affairs team. Until June 2017, Andrea was responsible for pharmacovigilance in Boehringer Ingelheim, Italy, where he managed pharmacovigilance activities for Veterinary and Human products. Since July 2017, is Head of Pharmacovigilance for Mylan Italia S.r.l., a Viatris company where he coordinates and manages pharmacovigilance activities for drugs, medical devices, food supplement and cosmetics.

YOU MAY BE INTERESTED IN

Back To Top